DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks.

Buse JB, Drucker DJ, Taylor KL, Kim T, Walsh B, Hu H, Wilhelm K, Trautmann M, Shen LZ, Porter LE

Diabetes care9 Mar 2010Cited by 267 (Europe PMC)

PMID20215461PMCIDPMC2875434DOI10.2337/dc09-1914PepBankPUB-20215461

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

01HumanRandomized controlled trialEfficacy outcome
In patients receiving weekly exenatide, 71% achieved A1C below 7.0% at week 52.
In plain wordsIn people receiving weekly exenatide, 71% reached A1C below 7.0%.
Peptide
Exenatide (exendin-4)
Outcome
Not applicableA1C below 7.0%
Study
n = 258
Outcome group
Glycemic control · Metabolic and weight
Studied dose
2 mg once weekly · 22-week extension after 30 weeks of weekly or twice-daily exenatideAs given in this study (human).
Measurements
Responders
71%
A1C <7.0%
Source sentences
Summary
At week 52, 71 and 54% of all patients achieved A1C <7.0% and <or=6.5%, respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
We now report the safety and efficacy of exenatide QW in 1) patients who continued treatment for an additional 22 weeks (52 weeks total) and 2) patients who switched from exenatide BID to exenatide QW after 30 weeks.
Summary · context
In this randomized, multicenter, comparator-controlled, open-label trial, 258 patients entered the 22-week open-ended assessment phase (n = 128 QW-only; n = 130 BID-->QW).
Report a problemFND-2021546103
02HumanRandomized controlled trialEfficacy outcome
In patients receiving weekly exenatide, 54% achieved the lower A1C target at week 52.
In plain wordsIn people receiving weekly exenatide, 54% reached the lower A1C target.
Peptide
Exenatide (exendin-4)
Outcome
Not applicableA1C at or below 6.5%
Study
n = 258
Outcome group
Glycemic control · Metabolic and weight
Studied dose
2 mg once weekly · 22-week extension after 30 weeks of weekly or twice-daily exenatideAs given in this study (human).
Measurements
Responders
54%
A1C <=6.5%
Source sentences
Summary
At week 52, 71 and 54% of all patients achieved A1C <7.0% and <or=6.5%, respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
We now report the safety and efficacy of exenatide QW in 1) patients who continued treatment for an additional 22 weeks (52 weeks total) and 2) patients who switched from exenatide BID to exenatide QW after 30 weeks.
Summary · context
In this randomized, multicenter, comparator-controlled, open-label trial, 258 patients entered the 22-week open-ended assessment phase (n = 128 QW-only; n = 130 BID-->QW).
Report a problemFND-2021546104
03HumanRandomized controlled trialEfficacy outcome
In both exenatide treatment arms, fasting plasma glucose fell by more than 40 mg/dl after 52 weeks.
In plain wordsIn people with diabetes, fasting glucose fell from baseline in both exenatide groups.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseFasting plasma glucose
Study
n = 258
Outcome group
Glycemic control · Metabolic and weight
Studied dose
2 mg once weekly · 22-week extension after 30 weeks of weekly or twice-daily exenatideAs given in this study (human).
Measurements
FPG reduction
> 40 mg/dl
both arms
Source sentences
Summary
In both treatment arms, FPG was reduced by >40 mg/dl, and body weight was reduced by >4 kg after 52 weeks.
2 context sentences(design, population, supporting numbers)
Summary · context
We now report the safety and efficacy of exenatide QW in 1) patients who continued treatment for an additional 22 weeks (52 weeks total) and 2) patients who switched from exenatide BID to exenatide QW after 30 weeks.
Summary · context
In this randomized, multicenter, comparator-controlled, open-label trial, 258 patients entered the 22-week open-ended assessment phase (n = 128 QW-only; n = 130 BID-->QW).
Report a problemFND-2021546105
04HumanRandomized controlled trialEfficacy outcome
In both exenatide treatment arms, body weight fell by more than 4 kg after 52 weeks.
In plain wordsIn people with diabetes, body weight fell from baseline in both exenatide groups.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseBody weight
Study
n = 258
Outcome group
Body weight · Metabolic and weight
Studied dose
2 mg once weekly · 22-week extension after 30 weeks of weekly or twice-daily exenatideAs given in this study (human).
Measurements
Weight reduction
> 4 kg
both arms
Source sentences
Summary
In both treatment arms, FPG was reduced by >40 mg/dl, and body weight was reduced by >4 kg after 52 weeks.
2 context sentences(design, population, supporting numbers)
Summary · context
We now report the safety and efficacy of exenatide QW in 1) patients who continued treatment for an additional 22 weeks (52 weeks total) and 2) patients who switched from exenatide BID to exenatide QW after 30 weeks.
Summary · context
In this randomized, multicenter, comparator-controlled, open-label trial, 258 patients entered the 22-week open-ended assessment phase (n = 128 QW-only; n = 130 BID-->QW).
Report a problemFND-2021546106
05HumanRandomized controlled trialSafety outcome
In patients receiving weekly exenatide, nausea occurred less frequently during the extension and was predominantly mild.
In plain wordsIn people receiving weekly exenatide, nausea was less frequent than earlier and was mostly mild.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseNausea
Study
n = 258
Comparator
earlier assessment period
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
2 mg once weekly · 22-week assessment periodAs given in this study (human).
Source sentences
Summary
Nausea occurred less frequently in this assessment period and was predominantly mild.
2 context sentences(design, population, supporting numbers)
Summary · context
We now report the safety and efficacy of exenatide QW in 1) patients who continued treatment for an additional 22 weeks (52 weeks total) and 2) patients who switched from exenatide BID to exenatide QW after 30 weeks.
Summary · context
In this randomized, multicenter, comparator-controlled, open-label trial, 258 patients entered the 22-week open-ended assessment phase (n = 128 QW-only; n = 130 BID-->QW).
Report a problemFND-2021546107
06HumanRandomized controlled trialSafety outcome
In patients receiving weekly exenatide, no major hypoglycemia was observed during the extension.
In plain wordsIn people receiving weekly exenatide, no major hypoglycemia occurred during the extension.
Peptide
Exenatide (exendin-4)
Outcome
Not applicableMajor hypoglycemia
Study
n = 258
Outcome group
Adverse events · Metabolic and weight
Studied dose
2 mg once weekly · 22-week assessment periodAs given in this study (human).
Source sentences
Summary
No major hypoglycemia was observed.
2 context sentences(design, population, supporting numbers)
Summary · context
We now report the safety and efficacy of exenatide QW in 1) patients who continued treatment for an additional 22 weeks (52 weeks total) and 2) patients who switched from exenatide BID to exenatide QW after 30 weeks.
Summary · context
In this randomized, multicenter, comparator-controlled, open-label trial, 258 patients entered the 22-week open-ended assessment phase (n = 128 QW-only; n = 130 BID-->QW).
Report a problemFND-2021546108
07HumanRandomized controlled trialEfficacy outcome
In patients switching from twice-daily to weekly exenatide, A1C improved further and matched the continuing group's reduction at week 52.
In plain wordsIn people with diabetes, switching to weekly exenatide further improved A1C and matched the continuing weekly group's reduction.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseA1C after switching to weekly treatment
Study
n = 130
Outcome group
Glycemic control · Metabolic and weight
Studied dose
2 mg once weekly · 22 weeks after 30 weeks BIDAs given in this study (human).
Measurements
Mean A1C
6.6%
both groups at week 52
Source sentences
Summary
Patients switching from exenatide BID to exenatide QW achieved further A1C improvements; both groups exhibited the same A1C reduction and mean A1C (6.6%) at week 52.
2 context sentences(design, population, supporting numbers)
Summary · context
We now report the safety and efficacy of exenatide QW in 1) patients who continued treatment for an additional 22 weeks (52 weeks total) and 2) patients who switched from exenatide BID to exenatide QW after 30 weeks.
Summary · context
In this randomized, multicenter, comparator-controlled, open-label trial, 258 patients entered the 22-week open-ended assessment phase (n = 128 QW-only; n = 130 BID-->QW).
Report a problemFND-2021546102
08HumanRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes continuing weekly exenatide, A1C remained reduced through week 52.
In plain wordsIn people with diabetes continuing weekly exenatide, A1C remained lower than baseline.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseA1C continued weekly treatment
Study
n = 128
Outcome group
Glycemic control · Metabolic and weight
Studied dose
2 mg once weekly · 52 weeksAs given in this study (human).
Measurements
A1C change
−2%
continued weekly exenatide
A1C change CI
−2.1 to −1.8%
95% CI
Source sentences
Summary
Patients continuing exenatide QW maintained A1C improvements through 52 weeks (least squares mean -2.0% [95% CI -2.1 to -1.8%]).
2 context sentences(design, population, supporting numbers)
Summary · context
We now report the safety and efficacy of exenatide QW in 1) patients who continued treatment for an additional 22 weeks (52 weeks total) and 2) patients who switched from exenatide BID to exenatide QW after 30 weeks.
Summary · context
In this randomized, multicenter, comparator-controlled, open-label trial, 258 patients entered the 22-week open-ended assessment phase (n = 128 QW-only; n = 130 BID-->QW).
Report a problemFND-2021546101

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT00308139

Effects of Exenatide Long-Acting Release on Glucose Control and Safety in Subjects With Type 2 Diabetes Mellitus(DURATION - 1)

AstraZenecan = 303Apr 2006 to Aug 2014

Type 2 Diabetes Mellitus

Trial page ClinicalTrials.govUpdated 26 Aug 2015

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.